569 related articles for article (PubMed ID: 35754218)
21. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
[TBL] [Abstract][Full Text] [Related]
22. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
Zhao L; Liu R; Zhang Z; Li T; Li F; Liu H; Li G
Colorectal Dis; 2016 Aug; 18(8):763-72. PubMed ID: 27169752
[TBL] [Abstract][Full Text] [Related]
23. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis.
Zhu Y; Chen J; Sun X; Lou Y; Fang M; Zhou F; Zhang L; Xin Y
Front Oncol; 2023; 13():1177557. PubMed ID: 37228495
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of total neoadjuvant therapy in locally advanced rectal cancer: a meta-analysis.
Xiong K; Bao T; Cao Y; Hu W; Deng J; Chen J; Xiao T
Int J Colorectal Dis; 2023 Apr; 38(1):89. PubMed ID: 37004572
[TBL] [Abstract][Full Text] [Related]
25. Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM).
Capelli G; De Simone I; Spolverato G; Cinquini M; Moschetti I; Lonardi S; Masi G; Carlomagno C; Corsi D; Luppi G; Gambacorta MA; Valvo F; Cannizzaro R; Grillo F; Barbaro B; Restivo A; Messina M; Pastorino A; Aschele C; Pucciarelli S
J Gastrointest Surg; 2020 Sep; 24(9):2150-2159. PubMed ID: 32394125
[TBL] [Abstract][Full Text] [Related]
26. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A
BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032
[TBL] [Abstract][Full Text] [Related]
28. Current status of total neoadjuvant therapy for locally advanced rectal cancer.
Feng W; Yu B; Zhang Z; Li J; Wang Y
Asia Pac J Clin Oncol; 2022 Dec; 18(6):546-559. PubMed ID: 34818447
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial.
Mei WJ; Wang XZ; Li YF; Sun YM; Yang CK; Lin JZ; Wu ZG; Zhang R; Wang W; Li Y; Zhuang YZ; Lei J; Wan XB; Ren YK; Cheng Y; Li WL; Wang ZQ; Xu DB; Mo XW; Ju HX; Ye SW; Zhao JL; Zhang H; Gao YH; Zeng ZF; Xiao WW; Zhang XP; Zhang X; Xie E; Feng YF; Tang JH; Wu XJ; Chen G; Li LR; Lu ZH; Wan DS; Bei JX; Pan ZZ; Ding PR
Ann Surg; 2023 Apr; 277(4):557-564. PubMed ID: 36538627
[TBL] [Abstract][Full Text] [Related]
30. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.
Liang Z; Chen T; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
Medicine (Baltimore); 2024 Jan; 103(3):e36785. PubMed ID: 38241577
[TBL] [Abstract][Full Text] [Related]
32. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
34. [The safety and efficacy of radical surgery after modified total neoadjuvant therapy for locally advanced rectal cancer].
Zhang L; Yu L; Wu YL; Zhang QQ; Shen SH; Li DD; Fang H; Yang L; Zhang HZ
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):501-506. PubMed ID: 32575948
[No Abstract] [Full Text] [Related]
35. Total neoadjuvant therapy versus standard neoadjuvant treatment strategies for the management of locally advanced rectal cancer: network meta-analysis of randomized clinical trials.
Donnelly M; Ryan OK; Ryan ÉJ; Creavin B; O'Reilly M; McDermott R; Kennelly R; Hanly A; Martin ST; Winter DC
Br J Surg; 2023 Sep; 110(10):1316-1330. PubMed ID: 37330950
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
37. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis.
Ding M; Zhang J; Hu H; Cai Y; Ling J; Wu Z; Xie X; Li J; Li W; Deng Y
Clin Colorectal Cancer; 2022 Mar; 21(1):e12-e20. PubMed ID: 34963563
[TBL] [Abstract][Full Text] [Related]
38. Prolonged interval to surgery following neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A meta-analysis of randomized controlled trials.
Owens PW; Saeed M; McCawley N; Loughlin P; Kearney DE; Burke JP; McNamara DA; Sahebally SM
Surgeon; 2024 Jun; 22(3):166-173. PubMed ID: 38521683
[TBL] [Abstract][Full Text] [Related]
39. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
[TBL] [Abstract][Full Text] [Related]
40. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]